An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
ApexOnco Front Page
Recent articles
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
The group toplines a phase 2 win with Alphamedix.
And Treeline and HengRui also get in on the pan-RAS act.
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
The group’s $8bn acquisition of Merus was the standout in the third quarter.
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
Key FDA decisions are expected to face delays.
